9 results
10-K
2021 FY
TYRA
Tyra Biosciences Inc
3 Mar 22
Annual report
4:31pm
and regulations with respect to drug pricing and payments and other transfers of value made by pharmaceutical manufacturers to physicians and other … , drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than
10-Q
2021 Q3
TYRA
Tyra Biosciences Inc
3 Nov 21
Quarterly report
4:31pm
and efficacy of our product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing … drug pricing program; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; created a new Medicare
424B4
TYRA
Tyra Biosciences Inc
15 Sep 21
Prospectus supplement with pricing info
4:10pm
and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out … eligible for discounts under the 340B drug pricing program; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug
S-1/A
nzzp cbuww
9 Sep 21
IPO registration (amended)
6:08am
S-1
xfqj yg40a4h
20 Aug 21
IPO registration
4:07pm
DRS/A
cgyt 0wcp
2 Jul 21
Draft registration statement (amended)
12:00am
DRS
83csm4r pr8q2s
28 May 21
Draft registration statement
12:00am
- Prev
- 1
- Next